- Home
- NUVL vs LEA Comparison
NUVL vs LEA Comparison
Compare NUVL & LEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- LEA
- Stock Information
- Founded
- NUVL 2017
- LEA 1917
- Country
- NUVL United States
- LEA United States
- Employees
- NUVL N/A
- LEA N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- LEA Auto Parts:O.E.M.
- Sector
- NUVL Health Care
- LEA Consumer Discretionary
- Exchange
- NUVL Nasdaq
- LEA Nasdaq
- Market Cap
- NUVL 6.5B
- LEA 5.4B
- IPO Year
- NUVL 2021
- LEA N/A
- Fundamental
- Price
- NUVL $98.17
- LEA $103.52
- Analyst Decision
- NUVL Strong Buy
- LEA Buy
- Analyst Count
- NUVL 11
- LEA 11
- Target Price
- NUVL $121.45
- LEA $115.91
- AVG Volume (30 Days)
- NUVL 527.5K
- LEA 511.3K
- Earning Date
- NUVL 10-30-2025
- LEA 10-31-2025
- Dividend Yield
- NUVL N/A
- LEA 2.98%
- EPS Growth
- NUVL N/A
- LEA N/A
- EPS
- NUVL N/A
- LEA 8.57
- Revenue
- NUVL N/A
- LEA $22,889,700,000.00
- Revenue This Year
- NUVL N/A
- LEA N/A
- Revenue Next Year
- NUVL N/A
- LEA $1.85
- P/E Ratio
- NUVL N/A
- LEA $12.08
- Revenue Growth
- NUVL N/A
- LEA N/A
- 52 Week Low
- NUVL $55.54
- LEA $73.85
- 52 Week High
- NUVL $104.90
- LEA $113.10
- Technical
- Relative Strength Index (RSI)
- NUVL 60.96
- LEA 55.78
- Support Level
- NUVL $90.00
- LEA $100.70
- Resistance Level
- NUVL $99.94
- LEA $104.76
- Average True Range (ATR)
- NUVL 5.06
- LEA 2.15
- MACD
- NUVL 0.69
- LEA 0.63
- Stochastic Oscillator
- NUVL 66.81
- LEA 85.78
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About LEA Lear Corporation
Lear Corp designs, develops, and manufactures automotive seating and electrical systems and components. The company has two reporting segments Seating and E-Systems. Seating components include frames and mechanisms, covers (leather and woven fabric), seat heating and cooling, foam, and headrests. Automotive electrical distribution and connection systems and electronic systems include wiring harnesses, terminals and connectors, on-board battery chargers, high-voltage battery management systems. The company earns majority of its revenue from the seating segment.